Quarterly Magazine Archive
Inflection Point: AI, Genomics and Governance Remap Biotech — Q2 2026 Review
Published July 25, 2026 | 3 articles analyzed
Read IssueMomentum and Measures: AI, Genomics and the Governance Stress-Test — Q2 2026
Published July 25, 2026 | 3 articles analyzed
Read IssueBioCircuit Q1 2026: From Pilots to Patients — Regulatory Wins, Manufacturing Strain, and the Governance Gap
Published July 25, 2026 | 4 articles analyzed
Read IssueInflection Point: AI, Genomics and Governance Shape Q2 2026 Biotech
Published July 25, 2026 | 3 articles analyzed
Read IssueFrom Lab to Ledger: Q1 2026's Push from Breakthroughs to Bedside—and the Systems That Will Decide Who Gets Them
Published July 25, 2026 | 4 articles analyzed
Read IssueFrom Bench to Bedside — Q1 2026's Push for Translation, Scale and Social License
Published July 25, 2026 | 4 articles analyzed
Read IssueFrom Approval to Access: Q1 2026's Push to Translate Breakthroughs into Care
Published July 25, 2026 | 4 articles analyzed
Read IssueFrom Proof to Practice: Q1 2026’s Push Toward Commercialization, Control, and Coverage
Published July 25, 2026 | 4 articles analyzed
Read IssueFrom Lab to Ledger: Q1 2026's Pivot from Discovery to Delivery
Published July 25, 2026 | 4 articles analyzed
Read IssueFrom Bench to Bedside: Commercialization, Capacity, and the Governance Tests of Q1 2026
Published July 25, 2026 | 4 articles analyzed
Read IssueFrom Lab Bench to Bedside: Q1 2026's Move from Innovation to Implementation
Published July 25, 2026 | 4 articles analyzed
Read IssueInflection and Accountability: Q2 2026 in Biotech — From Agentic Labs to Access Failures
Published July 25, 2026 | 3 articles analyzed
Read IssueInflection Points: AI, Genomics and Governance in Q2 2026
Published July 25, 2026 | 3 articles analyzed
Read Issue